STAAR Surgical (STAA) to Release Earnings on Tuesday

STAAR Surgical (NASDAQ:STAA) will be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect STAAR Surgical to post earnings of $0.05 per share for the quarter. STAAR Surgical has set its FY24 guidance at $0.70 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The business had revenue of $76.27 million for the quarter, compared to the consensus estimate of $75.94 million. During the same quarter in the prior year, the business posted $0.04 earnings per share. STAAR Surgical’s revenue for the quarter was up 19.1% on a year-over-year basis. On average, analysts expect STAAR Surgical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $45.51 on Friday. The firm’s 50 day moving average price is $41.38 and its 200-day moving average price is $35.83. STAAR Surgical has a 52-week low of $26.66 and a 52-week high of $69.00. The company has a market cap of $2.24 billion, a PE ratio of 105.84 and a beta of 0.80.

Insider Transactions at STAAR Surgical

In related news, Director Aimee S. Weisner acquired 1,750 shares of the stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $38.11 per share, for a total transaction of $66,692.50. Following the completion of the purchase, the director now owns 10,864 shares of the company’s stock, valued at approximately $414,027.04. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $50.00 price objective on shares of STAAR Surgical in a research note on Monday, April 1st. Mizuho raised their target price on shares of STAAR Surgical from $45.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Piper Sandler lowered their target price on shares of STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, February 27th. Canaccord Genuity Group raised their target price on shares of STAAR Surgical from $32.00 to $46.00 and gave the company a “hold” rating in a research note on Monday, April 8th. Finally, William Blair upgraded shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 4th. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and an average price target of $46.38.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.